Introduction: Chemotherapy-induced neuropathies are one of the most common side effects of cancer treatment, surpassing bone marrow suppression and kidney dysfunction. Chemotherapy effects on the nervous system vary between different classes of drugs and depend on specific chemical and physical properties of the drug used. The three most neurotoxic classes of anti-cancer drugs are: platinum-based drugs, taxanes, and thalidomide and its analogs; other, less neurotoxic but also commonly used drugs are: bortezomib, ixabepilone, and vinca alkaloids.
Chemotherapy-induced polyneuropathies are one of the most common side effects of cancer treatment, surpassing bone marrow suppression and kidney dysfunction. The effects of chemotherapy on the nervous system vary between different classes of drugs and depend on specific chemical and physical properties of the drug used. Observed symptoms range from acute, transient thermal sensation to permanent, accumulative changes in peripheral nerves accompanied by chronic pain and irreversible nerve damage. These symptoms affect patient motor ability, often requiring extensive physical therapy and posing a heavy burden for health care providers (Lema, Foley, & Hausheer, 2010) .
Chemotherapeutics exerting neurotoxic effects on the peripheral nervous system are often the ones that are also most commonly used, often listed as a standard, routine medication for most common types of cancer (WHO, 2014) . Among them, the three most neurotoxic classes of anti-cancer drugs are: platinum-based drugs, taxanes, and thalidomide and its analogs; other, less neurotoxic but also commonly used drugs are: bortezomib, ixabepilone, and vinca alkaloids (Table 1) .
Here, in this paper, we aim to provide a short review of the most common, neuropathy-inducing anti-cancer drugs, describe the most prevalent neuropathy symptoms produced by each of them, and outline preventive measures and treatment guidelines for cancer patients suffering from neuropathy and for their health care providers.
| PLATINUM-BASED DRUGS
Platinum-based drugs, sometimes referred as to platins, such as oxaliplatin, cisplatin, and carboplatin belong to a large class of synthetic anti-cancer drugs whose main antineoplastic action is triggered by DNA-cross-linking-inhibiting cancer cell DNA synthesis and repair (Kelland & Farrell, 2000) . Platinum-based drugs are enlisted on the WHO Model List of Essential Medicines which represents the most important medications in a basic health system (WHO, 2014) and are used in the treatment of a variety of tumors, from lung and ovarian cancers to bladder, germ cell, testicular, and colorectal cancers.
Neurotoxicity is their main dose-limiting side effect and affects a large number of platin-treated patients, with neuropathy incidence rate ranging from 70% to 100% of all treated patients (McWhinney, Goldberg, & McLeod, 2009 ). These numbers make platinum-based drugs the most neurotoxic anti-cancer drugs available on market. Among platins, oxaliplatin evokes the most varied and unique neurotoxic effects, making it detrimental among available classes of anti-cancer drugs.
Platin-induced neurotoxic effects include dysesthesias, tingling, and burning sensation and neuropathic pain. Using electrophysiological techniques, peripheral nerve changes are diagnosed as mononeuropathies such as carpal tunnel syndrome or mild to severe sensory and sensorimotor polyneuropathies of axonal origin. Studies suggest that the neurotoxic effects are triggered by drug accumulation in the dorsal root ganglia, causing neuronal dysfunction and apoptosis, thus leading to long-term, often, irreversible changes in the peripheral nervous system (Avan et al., 2015; Park et al., 2015) .
In case of oxaliplatin, additional transient post IV infusion neurotoxic effects have also been observed, which have often been described as jaw tightening, eye pain, leg cramps, pseudolaryngospasm, and cold hypersensitivity. These symptoms usually occur 30-60 min post infusion and resolve within a couple of days (Argyriou et al., 2013; Avan et al., 2015) . The mechanisms underlying these transient neurotoxic effects remain unclear; however, recent studies indicate that they might be a direct result of structural properties of oxaliplatin. An oxalate, as part of the oxaliplatin chemical compound, released during oxaliplatin metabolism, binds to calcium through chelation, blocking calcium channels and altering neuronal signal transduction (Avan et al., 2015; McWhinney et al., 2009 ).
| TAXANES
Taxanes are a class of diterpenoids and include: paclitaxel (Taxol), docetaxel (Taxotere), and cabazitaxel (Jevtana) that act on microtubules, effectively preventing cancer cell division (Abal, Andreu, & Barasoain, 2003 incidence ranges from 11% to 87%, the highest rates of which are reported for paclitaxel (Park et al., 2014; Scripture, Figg, & Sparreboom, 2006) . Neurological symptoms include paresthesias and dysesthesias of toes, finger numbness, and loss of dexterity (Pace et al., 1997) .
Using electrophysiological techniques, patients were predominately diagnosed with moderate axonal sensory neuropathy; however, rare cases of sensorimotor polyneuropathy and carpal tunnel syndrome were observed as well (Vahdat et al., 2001) . The mechanism of taxane-induced neurotoxicity remains elusive; however, growing evidence indicates that a disturbance of axonal transport and neuronal oxidative stress might be the leading factors resulting in neuropathic changes in taxane-treated cancer patients (Shemesh & Spira, 2010) .
| THALIDOMIDE AND ITS ANALOGS
Thalidomide (sold as Immunoprin, Talidex, Talizer, or Thalomid) and its synthetic analogs such as lenalidomide, pomalidomide, and apremilast belong to the family of antiangiogenic and immunomodulatory drugs used in multiple myeloma treatment (Hideshima et al., 2000) .
Neurotoxic effects of thalidomide are predominately observed in lower extremities neuropathies, such as foot and leg dysesthesia, sensory loss, tingling, impaired reflexes, and painful muscle cramps. Using electrophysiological techniques, thalidomide-induced neurotoxicity is observed as impaired nerve conduction velocity, altered amplitude, and H reflex absence and in the vast majority of patients is diagnosed as sensory or sensorimotor polyneuropathy of primarily axonal origin.
It is estimated that thalidomide-induced polyneuropathy affects from 20% to 60% of all thalidomide-treated cancer patients (Cavaletti et al., 2004; Clemmensen, Olsen, & Andersen, 1984; Plasmati et al., 2007) .
The mechanism of thalidomide-induced neurotoxicity is not completely clear; however, studies suggest that it might be prompted by nuclear factor-kappaB-related dysregulation of neurotrophins that are critical for sensory neuron survival . Furthermore, growing evidence indicates that old age and pre-existing predisposition to nerve diseases resulting from a polymorphism of genes involved in nerve repair might play a crucial role in developing a thalidomide-induced polyneuropathy .
| BORTEZOMIB
Bortezomib (sold as Velcade or Cytomib) is a proteasome inhibitor used in multiple myeloma and mantle cell lymphoma treatment. It is a very potent drug, often used when other antineoplastic agents fail (Chen, Frezza, Schmitt, Kanwar, & Dou, 2011; Richardson, Hideshima, & Anderson, 2003 (Argyriou, Iconomou, & Kalofonos, 2008; Meregalli, 2015) . Surprisingly, studies showed that cancer therapy involving both bortezomib and thalidomide reduced incidence of chemotherapy-induced neuropathies in cancer patients, suggesting that both substances might cancel each other's neurotoxic activity in the course of treatment (Chaudhry, Cornblath, Polydefkis, Ferguson, & Borrello, 2008) . (Vahdat et al., 2012) . As with other chemotherapeutics, the mechanisms underlying ixabepilone neurotoxicity remain unclear. Limited available evidence shows that ixabepilone neurotoxicity might be due to increased deposits of the drug in peripheral neurons, triggering mitochondrial dysfunction and increased oxidative stress in affected neurons (Ebenezer et al., 2014) .
| IXABEPILONE

| VINCA ALKALOIDS
Vinca alkaloids, such as vinblastine, vinorelbine, vincristine, and vindesine belong to a class of widely used plant-derived drugs used in the treatment of different types of cancers, including but not limited to lung, brain, bladder, and testicular cancer (O'Marcaigh & Betcher, 1995) . Among vinca alkaloids, vinblastine is the most commonly used anti-cancer drug, listed in the WHO Model List of Essential Medicines (WHO, 2014) . Vinca alkaloids bind tubulin; thus, preventing microtubule formation and inhibiting cancer cell division (Jordan, Thrower, & Wilson, 1991) . Vinca alkaloids trigger neuropathy in about 20% of cancer patients; typical symptoms include lower limb weakness, sensory impairment, altered gait, and diminished reflexes. Using electrophysical techniques, nerve changes are diagnosed as predominantly moderate to severe sensory or sensorimotor polyneuropathies (Ness et al., 2013) . Mechanisms underlying neurotoxicity of vinca alkaloids remain unclear; however, available evidence suggests that genetic polymorphism of genes crucial for microtubule formation might play a role in developing neuropathy in cancer patients (Diouf et al., 2015) .
| DIAGNOSTIC TECHNIQUES
Neurophysiological techniques and nerve biopsies are useful tools for diagnosis and assessment of functional nerve damage (Boruchow & Gibbons, 2013; Themistocleous, Ramirez, Serra, & Bennett, 2014) . Skin biopsies have shown 88.4% diagnostic efficacy (Devigili et al., 2008) .
A standard skin punch biopsy 3 mm in diameter can be taken 10 cm proximal to the lateral malleolus (Lauria et al., 2010 Conventional nerve conduction velocity studies include the examination of large myelinated fibers; however, the main limitation of this method is its inability to detect changes in small fibers (Themistocleous et al., 2014) .
Quantitative sensory testing is another noninvasive, standardized technique for psychophysical threshold evaluation of cold and warm sensations-thermal detection, pain thresholds, and stimuli-response function (Devigili et al., 2008; Themistocleous et al., 2014) . Furthermore, this kind of testing can assess the function of thin and unmyelinated nerve fibers (Verberne, Wiggers, Vermeulen, & de Jong, 2013) .
Furthermore, there are new diagnostic techniques such as the measurement of nerve fiber density using corneal confocal microscopy and nociceptive evoked potentials (Hoeijmakers, Faber, Lauria, Merkies, & Waxman, 2012) . Nerve morphology can be assessed using in vivo corneal confocal microscopy, including corneal nerve fiber density, that is, the number of nerve fibers/mm 2 , corneal nerve branch density-the number of branch points in the main nerves/mm 2 and corneal fiber length-the total length of nerves mm/mm 2 (Ferdousi et al., 2015) . In patients with chemotherapy-induced peripheral neuropathy, using in vivo corneal confocal microscopy revealed an increase in corneal nerve fiber length. This observation correlated with nerve regeneration (Ferdousi et al., 2015) . 
| PHARMACOGENETIC TECHNIQUES
Pharmacogenetic techniques are used to identify genes that may be useful in identifying patients at higher risk of developing chemotherapy-induced peripheral neuropathies. Nowadays, many trials assessing the interaction between gene-and chemotherapyinduced peripheral neuropathy are conducted. Progressive DNAadduct accumulation and inhibition of DNA repair pathways (e.g., extracellular signal-regulated kinase 1/2, c-Jun N-terminal kinase/ stress-activated protein kinase, and p38 mitogen-activated protein kinase) are the main reasons for peripheral nerve and dorsal root ganglia neuron damage during cisplatin and carboplatin therapy. In case of oxaliplatin, polymorphisms of genes affecting the activity of pivotal metal transporters or voltage-gated sodium channel genes (e.g., organic cation transporters, organic cation/carnitine transporters, and some metal transporters, such as copper transporters and multidrug resistance-associated proteins) increase oxaliplatin neurotoxicity and treatment response (Avan et al., 2015) . A Japanese study of colorectal cancer patients treated with oxaliplatin-based chemotherapy estimated the pharmacogenetic correlation between neuropathy and polymorphisms of the excision repair cross-complementation Group 1 (ERCC1) and glutathione-S-transferases pi 1 (GSTP1) genes. The study revealed that polymorphisms of ERCC1, C118T, and GSTP1 Ile105Val made patients more susceptible to oxaliplatin-induced neuropathy (Inada et al., 2010) . Patients carrying CYP3A4 defective variants had more severe neuropathy and higher probability of neuropathyinduced paclitaxel treatment modifications; hence, CYP3A4 defective variants are a genetic marker associated with paclitaxel treatment modifications caused by neuropathy (Apellaniz-Ruiz et al., 2015) .
| CHEMOTHERAPY-INDUCED NEUROPATHIES-WHAT CAN WE DO?
As discussed here, a large body of evidence suggests that chemotherapy-induced neuropathies are highly prevalent among cancer patients, constituting a major problem both for cancer patients and survivors as well as for their health care providers. The important question arises-is it possible to prevent and/or alleviate chemotherapy-induced neuropathy symptoms without jeopardizing cancer treatment regimens and incurring additional treatment costs?
The answer should be affirmative. It is possible to reduce the number of chemotherapy-induced neuropathies and lower their financial burden on patients and health care provides, but in order to do so efficiently, we would need to revise patient examination and treatment protocols. Revised protocols should reflect our knowledge of chemotherapeutic neurotoxicity and encourage larger involvement of primary care physicians and neurologists in cancer treatment protocols.
T A B L E 2 Randomized controlled trials concerning prevention and treatment of chemotherapy-induced peripheral neuropathy according to Brami, Bao, and Deng (2016) The most important studies concerning preventions and treatment of chemotherapy-induced peripheral neuropathy, which have been conducted so far, are presented in Table 2 
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